Chicago, ILNCT07207148Now EnrollingIRB Ready

Multiple Sclerosis Clinical Trial in Chicago, IL

Access cutting-edge multiple sclerosis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access multiple sclerosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple sclerosis treatment provided free

Apply for This Chicago Location

Check if you qualify for this multiple sclerosis clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Multiple Sclerosis Study in Chicago

The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Diagnosis of MS (2019 revised McDonald criteria) of any type (PPMS, RRMS, SPMS) by a neurologist,
Adult age 18-70 years,
BMI \>=24.0 kg/m2,
Taken at least one dose of Ocrelizumab prior to study entry,
EDSS \<7.0,
Able to provide individual informed consent,
MRI available to confirm the diagnosis of MS.

Exclusion Criteria

Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,
Current clinical trial participant,
Unable to speak a language for which translation can be found in the hospital system,
Unclear documentation of MS diagnosis or prior or current MS treatment,
Relapse within the past 3 months,
Recent major surgical procedure in the past 6 months,
Exposure to steroids (systemic) within the past 3 months,
Not on Ocrelizumab in the past \>9 months,
Moribund status,
Underweight or experiencing protein malnutrition,
Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, dementia, etc.),
Unable to complete the study activities for any reason as deemed by the study investigator. Additional Inclusion Criteria Aim 1:
Exposed to GLP-1 agonist treatment in the last 3 years or less, or starting on a GLP-1 agonist in the coming \<3 months,
Willing to report monthly patient-reported outcomes remotely or in-person. Additional Inclusion Criteria Aim 2:
Able to present for baseline and follow up in person,
Unexposed to a GLP-1 agonist in the past year,
Starting on a GLP-1 agonist in the next \<6 months,
Plan to be exposed to GLP-1 agonist for a minimum of 72 weeks following enrollment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07207148) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Sclerosis Treatment Options in Chicago, IL

If you're searching for multiple sclerosis treatment options in Chicago, IL, this clinical trial (NCT07207148) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple sclerosis clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Chicago, IL

See all multiple sclerosis clinical trials recruiting in Chicago — not just this study.

Browse Multiple Sclerosis Trials in Chicago →

Browse More Trials by Condition

Multiple Sclerosis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL